Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VICI-DISEASE

Financiado

Cerrado

PROTECTION FROM VIRUSES WITH EPIDEMIC AND PANDEMIC DISEASE OUTBREAK POTENTIAL TH...

PROTECTION FROM VIRUSES WITH EPIDEMIC AND PANDEMIC DISEASE OUTBREAK POTENTIAL THROUGH DEVELOPMENT AND CLINICAL TESTING OF A NOVEL CAPSID VIRUS LIKE PARTICLE (CVLP) VACCINE The enormous health and economic impacts of epidemics and pandemics has become one of the defining public policy and health issues in Europe and throughout the world. A new urgency is required to understand, rapidly respond to, a... ver más

30/11/2027

UCPH

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-13

HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response:... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

UCPH

696.14K€ | Lider

PSG GOVINDASWAMY NAIDU & SON...

FLI

950.04K€ | Participante

EXPRES2ION

4.25M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

AGL2010-22200-C02-02 CARACTERIZACION DE LA RESPUESTA INMUNE INDUCIDA POR CEPAS DE... 157K€ Cerrado

VERDI SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics c... 15M€ Cerrado

PID2019-107001RB-I00 MECANISMOS DE PATOGENESIS EN CORONAVIRUS Y ESTRATEGIAS DE PR... 290K€ Cerrado

FLUPLAN Novel strategies to combat future influenza pandemics 2M€ Cerrado

VERDI SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics c... 15M€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-11-13
Fecha Fin: 2027-11-30

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The enormous health and economic impacts of epidemics and pandemics has become one of the defining public policy and health issues in Europe and throughout the world. A new urgency is required to understand, rapidly respond to, and vaccinate against viruses with epidemic and pandemic potential. The major challenge for the modern vaccines is the induction of long-term protective immunity, as clearly demonstrated by fast waning of protection for current COVID-19 vaccines. VICI-DISEASE is an ambitious project which combines existing cutting-edge expertise in a tried and tested consortium, with new advances in this critical field. The consortium’s main objective is to develop a vaccine candidate portfolio and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for further development (Phase 2&3) in case of pandemic outbreaks. The primary candidate will be Nipah virus (NiV), a high-mortality viral disease with no vaccines or treatments. Our vaccine is based on NiV G protein displayed on capsid Virus Like Particle (cVLP), enabled by adapting template processes from our recent COVID-19 vaccine (currently in Phase 3), and expected to provide best-in-class longevity as shown for COVID-19. The VICI-DISEASE consortium’s objective is to develop and perform a clinical proof-of-concept study for • a highly effective (>90% protection), • long-term protective (>2 years), • NiV virus cVLP vaccine, • by adapting template processes established for our COVID-19 vaccine (currently in Phase 3), • within 48 months in a Phase 1/2a clinical study, • to help protect medical workers and the public from future NiV and Hendra virus outbreaks, • and establish a pipeline of novel filovirus vaccines through pre-clinical proof-of-concept studies. We address the call topic by improving pandemic preparedness and response through development of a NiV vaccine to Ph1/2 and two filovirus vaccines to pre-clinical proof-of-concept.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores